INTRODUCTION {#s1}
============

Among the available systemically active antifungal agents, the echinocandins, including caspofungin, anidulafungin, and micafungin, and the azoles, such as fluconazole, voriconazole, isavuconazole, and posaconazole, are all employed empirically as directed therapy and for prophylaxis in patients with suspected or documented invasive fungal infection ([@B1][@B2][@B7]). Whereas fluconazole remains the most frequently employed antifungal globally, the use of the echinocandin class has steadily increased in academic and community hospital settings ([@B2], [@B4], [@B7][@B8][@B11]).

The documented potency, spectrum, and safety of the echinocandins have led many experts in infectious diseases to consider echinocandins to be initial therapy for treating candidemia ([@B5], [@B7], [@B9], [@B12]). A meta-analysis of randomized clinical trials comparing treatment for candidemia and invasive candidiasis (IC) showed that initial therapy with an echinocandin was a significant predictor of survival ([@B13]). Once clinically stable, de-escalation to an oral azole (usually fluconazole) is suggested for all patients ([@B1], [@B5], [@B7], [@B12], [@B14]).

Echinocandins have some important limitations, despite their proven safety and efficacy ([@B9], [@B15]). Most notably, the daily parenteral dosing requirement complicates administration postdischarge in patients requiring extended therapy. Indeed, much of the growth in outpatient antifungal expenditure, as documented in a recent survey of antifungal use in U.S. hospitals, was for echinocandins. This survey suggests that outpatient antifungal use may be increasing ([@B7]). Although step-down therapy from an echinocandin to fluconazole may partially address the outpatient antifungal expenditure, it is complicated by the increasing rates of resistance to fluconazole among common species of *Candida* ([@B1], [@B7], [@B9], [@B14], [@B16]). Other potential drawbacks of the available echinocandins for clinical application are the use of a fixed dose irrespective of body size or species susceptibility (S) and emerging resistance mediated by mutations in the *fks* genes ([@B15], [@B17]). It has been suggested that underdosing of echinocandins, coupled with poor penetration to certain body sites, may partially account for the emerging echinocandin resistance ([@B15], [@B18], [@B19]). An echinocandin that could be safely administered at higher doses to ensure optimal pharmacokinetic (PK) and pharmacodynamic (PD) features and target attainment may facilitate outpatient therapy, reduce the hospital stay, and possibly delay or prevent the development of echinocandin resistance, thus becoming an important step toward improving the ability to effectively manage candidemia and IC ([@B15], [@B20]).

Rezafungin (Cidara Therapeutics, Inc.) is a novel echinocandin that exhibits a prolonged half-life and that displays chemical stability in plasma, in aqueous solution, and at an elevated temperature ([@B15], [@B21][@B22][@B27]). The *in vitro* activity of rezafungin against *Candida* spp. has been shown to be comparable to that of other clinically available echinocandins ([@B2], [@B28][@B29][@B36]). Rezafungin is being developed for the treatment of candidemia and other forms of IC by once-weekly intravenous administration ([@B27]). A phase 3, randomized, double-blind, multicenter clinical trial of the efficacy and safety of rezafungin for injection compared with those of intravenous caspofungin followed by oral fluconazole step-down in the treatment of subjects with candidemia and/or IC ([ClinicalTrials.gov](http://ClinicalTrials.gov) registration number NCT03667690; ReSTORE) is under way.

In the present study, we examined the *in vitro* activity of rezafungin compared with that of the other systemically active antifungal agents by testing a global collection of 2,205 clinical isolates of yeasts (*Candida* and *Cryptococcus* spp.) and molds (*Aspergillus* spp.) obtained during the 2016 to 2018 SENTRY Surveillance Program. All isolates were submitted to broth microdilution (BMD) susceptibility testing following Clinical and Laboratory Standards Institute (CLSI) methods ([@B37], [@B38]).

(Some results have been presented, in part, for the individual years included in the study period, at the following scientific conferences: ASM Microbe 2018 \[[@B34]\], IDWeek 2018 \[[@B35]\], and IDWeek 2019 \[[@B36]\].)

RESULTS {#s2}
=======

Geographic distribution of *Candida* species. {#s2.1}
---------------------------------------------

Among the 1,904 *Candida* isolates submitted for testing from 2016 through 2018, 43.9% were Candida albicans, 19.6% were Candida glabrata, 17.3% were Candida parapsilosis, 10.3% were Candida tropicalis, 4.9% were Candida dubliniensis, and 4.0% were Candida krusei ([Table 1](#T1){ref-type="table"}). [Table 1](#T1){ref-type="table"} lists the frequencies of the most common species of *Candida* in each geographic region included in the SENTRY Program. C. albicans was most common in the Asia-Pacific (APAC) region (49.8%) and Europe (EUR) (49.6%) and least common in North America (NA; the United States and Canada; 34.1%), whereas C. glabrata was most common in NA (27.7%) and least common in Latin America (LATAM) (8.7%). C. parapsilosis and C. tropicalis were more common than C. glabrata in LATAM (20.2% and 20.2% versus 8.7%). C. tropicalis also was a frequent cause of IC in the APAC region (16.9%). C. krusei was more common in LATAM (6.2%), whereas C. dubliniensis was more common in NA (9.0%).

###### 

Species distribution of *Candida* isolates by geographic region: SENTRY Program, 2016 to 2018

  Region[^*a*^](#T1F1){ref-type="table-fn"}   No. of isolates tested   \% of isolates by species                              
  ------------------------------------------- ------------------------ --------------------------- ------ ------ ------ ----- -----
  APAC                                        237                      49.8                        15.2   12.2   16.9   2.1   3.8
  EUR                                         823                      49.6                        18.2   17.6   7.5    3.6   3.4
  LATAM                                       242                      43.0                        8.7    20.2   20.2   1.7   6.2
  NA                                          602                      34.1                        27.7   17.6   7.5    9.0   4.2
  Total                                       1,904                    43.9                        19.6   17.3   10.3   4.9   4.0

![](AAC.00099-20-t0001)

Abbreviations: APAC, Asia-Pacific; EUR, Europe; LATAM, Latin America; NA, North America.

Rezafungin activity against *Candida*, Cryptococcus neoformans var. *grubii*, and *Aspergillus* isolates. {#s2.2}
---------------------------------------------------------------------------------------------------------

Among the 6 species of *Candida* for which the results are shown in [Table 2](#T2){ref-type="table"}, rezafungin was most active against C. albicans (MIC~90~, 0.06 μg/ml), C. tropicalis (MIC~90~, 0.06 μg/ml), and C. krusei (MIC~90~, 0.06 μg/ml) and least active against C. parapsilosis (MIC~90~, 2 μg/ml). With minimal variation over the 3-year time period, the modal MIC values were 0.03 μg/ml for C. albicans, C. tropicalis, and C. krusei, 0.06 μg/ml for C. glabrata and C. dubliniensis, and 1 μg/ml for C. parapsilosis. The MIC distribution data were employed to develop tentative epidemiological cutoff values (ECVs) using the iterative statistical method recommended by the CLSI ([@B39]) to establish the wild-type (WT) distribution for rezafungin and each of the tested species. The ECV of rezafungin for each species was 0.12 μg/ml for C. albicans (99.8% WT), C. glabrata (95.7% WT), C. tropicalis (97.4% WT), and C. krusei (100.0% WT), 0.25 μg/ml for C. dubliniensis (100.0% WT), and 4 μg/ml for C. parapsilosis (100.0% WT) ([Table 2](#T2){ref-type="table"}). Overall, 98.5% of the *Candida* spp. tested, aside from C. parapsilosis, were inhibited by ≤0.12 μg/ml and 99.2% were inhibited by ≤0.25 μg/ml of rezafungin ([Table 2](#T2){ref-type="table"}). Rezafungin showed limited activity against Cryptococcus neoformans (MIC~90~, \>4 μg/ml) and was highly active against *Aspergillus* species (100% minimum effective concentration \[MEC~100~\], ≤0.03 μg/ml). The ECV calculated for Aspergillus fumigatus was 0.03 μg/ml.

###### 

Antimicrobial activity of rezafungin tested against the main organisms and organism groups from all years using the CLSI method

  Organism/organism group (no. of isolates)    No. (cumulative %) of isolates inhibited at MIC (μg/ml) of[^*a*^](#T2F1){ref-type="table-fn"}:   MIC (μg/ml)                                                                                                                                                       
  -------------------------------------------- ------------------------------------------------------------------------------------------------ ------------- ----------- ------------ ------------ ------------ ------------ ------------ ----------- ----------- ------------ ----------- ------------ -------- -------
  Candida albicans (835)                       11 (3.8)                                                                                         6 (5.8)       87 (10.4)   270 (42.8)   309 (79.8)   139 (96.4)   28 (99.8)    2 (100.0)                                                                  0.03     0.06
      2016 (276)                                                                                                                                              13 (4.7)    100 (40.9)   113 (81.9)   38 (95.7)    11 (99.6)    1 (100.0)                                                                  0.03     0.06
      2017 (267)                                                                                                                                              12 (4.5)    83 (35.6)    96 (71.5)    66 (96.3)    10 (100.0)                                                                              0.03     0.06
      2018 (292)                               11 (3.8)                                                                                         6 (5.8)       45 (21.2)   87 (51.0)    100 (85.3)   35 (97.3)    7 (99.7)     1 (100.0)                                                                  0.015    0.06
  Candida glabrata (374)                       1 (0.3)                                                                                          0 (0.3)       0 (0.3)     5 (1.6)      136 (38.0)   162 (81.3)   54 (95.7)    6 (97.3)     3 (98.1)    3 (98.9)    4 (100.0)                             0.06     0.12
      2016 (135)                                                                                                                                              0 (0.0)     1 (0.7)      38 (28.9)    65 (77.0)    27 (97.0)    3 (99.3)     0 (99.3)    0 (99.3)    1 (100.0)                             0.06     0.12
      2017 (121)                                                                                                                                                          0 (0.0)      33 (27.3)    60 (76.9)    20 (93.4)    2 (95.0)     3 (97.5)    2 (99.2)    1 (100.0)                             0.06     0.12
      2018 (118)                               1 (0.8)                                                                                          0 (0.8)       0 (0.8)     4 (4.2)      65 (59.3)    37 (90.7)    7 (96.6)     1 (97.5)     0 (97.5)    1 (98.3)    2 (100.0)                             0.03     0.06
  Candida parapsilosis (329)                                                                                                                                  0 (0.0)     1 (0.3)      0 (0.3)      0 (0.3)      1 (0.6)      5 (2.1)      62 (21.0)   134 (61.7   124 (99.4)   2 (100.0)                1        2
      2016 (94)                                                                                                                                                                                                  0 (0.0)      2 (2.1)      13 (16.0)   37 (55.3)   42 (100.0)                            1        2
      2017 (118)                                                                                                                                              0 (0.0)     1 (0.8)      0 (0.8)      0 (0.8)      0 (0.8)      2 (2.5)      14 (14.4)   48 (55.1)   51 (98.3)    2 (100.0)                1        2
      2018 (117)                                                                                                                                                                                    0 (0.0)      1 (0.9)      1 (1.7)      35 (31.6)   49 (73.5)   31 (100.0)                            1        2
  Candida tropicalis (196)                                                                                                                                    12 (6.1)    52 (32.7)    75 (70.9)    41 (91.8)    11 (97.4)    3 (99.0)     0 (99.0)    1 (99.5)    1 (100.0)                             0.03     0.06
      2016 (64)                                                                                                                                               3 (4.7)     20 (35.9)    24 (73.4)    12 (92.2)    3 (96.9)     0 (96.9)     0 (96.9)    1 (98.4)    1 (100.0)                             0.03     0.06
      2017 (54)                                                                                                                                               0 (0.0)     11 (20.4)    19 (55.6)    17 (87.0)    5 (96.3)     2 (100.00)                                                                 0.03     0.12
      2018 (78)                                                                                                                                 0 (0.0)       9 (11.5)    21 (38.5)    32 (79.5)    12 (94.9)    3 (98.7)     1 (100.0)                                                                  0.03     0.06
  Candida krusei (77)                                                                                                                                         0 (0.0)     22 (28.6)    31 (68.8)    17 (90.9)    7 (100.0)                                                                               0.03     0.06
      2016 (33)                                                                                                                                               0 (0.0)     8 (24.2)     17 (75.8)    7 (97.0)     1 (100.0)                                                                               0.03     0.06
      2017 (28)                                                                                                                                               0 (0.0)     3 (10.7)     12 (53.6)    10 (89.3)    3 (100.0)                                                                               0.03     0.12
      2018 (16)                                                                                                                                               0 (0.0)     11 (68.8)    2 (81.2)     0 (81.2)     3 (100.0)                                                                               0.015    0.12
  Candida dubliniensis (93)                    1 (1.1)                                                                                          0 (1.1)       1 (2.2)     4 (6.5)      30 (38.7)    39 (80.6)    18 (100.0)                                                                              0.06     0.12
      2016 (30)                                                                                                                                                           0 (0.0)      8 (26.7)     15 (76.7)    7 (100.0)                                                                               0.06     0.12
      2017 (28)                                                                                                                                               0 (0.0)     1 (3.6)      9 (35.7)     11 (75.0)    7 (100.0)                                                                               0.06     0.12
      2018 (35)                                1 (2.9)                                                                                          0 (2.9)       1 (5.7)     3 (14.3)     13 (51.4)    13 (88.6)    4 (100.0)                                                                               0.03     0.12
  Cryptococcus neoformans var. *grubii* (73)                                                                                                                                                                                                                       0 (0.0)      9 (12.3)    64 (100.0)   \>4      \>4
      2016 (27)                                                                                                                                                                                                                                                                 0 (0.0)     27 (100.0)   \>4      \>4
      2017 (25)                                                                                                                                                                                                                                                    0 (0.0)      7 (28.0)    18 (100.0)   \>4      \>4
      2018 (21)                                                                                                                                                                                                                                                    0 (0.0)      2 (9.5)     19 (100.0)   \>4      \>4
  Aspergillus fumigatus (183)                                                                                                                   3 (4.0)       64 (36.6)   88 (84.7)    28 (100.0)                                                                                                        0.015    0.03
      2016 (48)                                                                                                                                               26 (54.2)   20 (95.8)    2 (100.0)                                                                                                         ≤0.008   0.015
      2017 (60)                                                                                                                                               25 (41.7)   29 (90.0)    6 (100.0)                                                                                                         0.015    0.015
      2018 (75)                                0 (0.0)                                                                                          3 (4.0)       13 (21.3)   39 (73.3)    20 (100.0)                                                                                                        0.015    0.03
  *Aspergillus* section *Flavi* (45)                                                                                                            5 (33.3)      20 (55.6)   18 (95.6)    2 (100.0)                                                                                                         ≤0.008   0.015
      2016 (12)                                                                                                                                               3 (25.0)    7 (83.3)     2 (100.0)                                                                                                         0.015    0.03
      2017 (18)                                                                                                                                               8 (44.4)    10 (100.0)                                                                                                                     0.015    0.015
      2018 (15)                                0 (0.0)                                                                                          5 (33.3)      9 (93.3)    1 (100.0)                                                                                                                      0.008    0.008
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During the 2016 and 2017 study years, the lowest echinocandins concentration tested was 0.008 μg/ml. The range was expanded to 0.002 μg/ml in 2018.

\>, greater than the last concentration tested.

Rezafungin and comparator *in vitro* activity against *Candida*, C. neoformans var. *grubii*, and *Aspergillus* isolates. {#s2.3}
-------------------------------------------------------------------------------------------------------------------------

Rezafungin (MIC~50/90~, 0.03/0.06 μg/ml; 99.8% WT) displayed activity against C. albicans comparable to that of anidulafungin, micafungin, and caspofungin (MIC~50/90~, 0.015/0.03 μg/ml \[anidulafungin, caspofungin, and micafungin\]) ([Table 3](#T3){ref-type="table"}). One C. albicans isolate was resistant (MIC, 1 μg/ml) to both caspofungin and micafungin and non-wild type (NWT \[in which the MIC is greater than the ECV\]; 0.25 μg/ml) to rezafungin while harboring a mutation in *fks1* hot spot (HS) region 1 (HS1; S645P) ([Table 4](#T4){ref-type="table"}). Three fluconazole-resistant strains were detected; one was from LATAM, and two were from NA ([Table 5](#T5){ref-type="table"}).

###### 

Antimicrobial activity of rezafungin and comparator agents tested against fungal isolates from the worldwide 2016 to 2018 rezafungin surveillance program[^*a*^](#T3F1){ref-type="table-fn"}

  Antimicrobial agent                                MIC (μg/ml)   CLSI[^*b*^](#T3F2){ref-type="table-fn"}   ECV[^*b*^](#T3F2){ref-type="table-fn"}                   
  -------------------------------------------------- ------------- ----------------------------------------- ----------------------------------------- ------ ------- ------
  Candida albicans (*n* = 835)                                                                                                                                        
      Rezafungin                                     0.03          0.06                                                                                       99.8    0.2
      Anidulafungin                                  0.015         0.03                                      100.0                                     0.0    100.0   0.0
      Caspofungin                                    0.015         0.03                                      99.9                                      0.1            
      Micafungin                                     0.015         0.03                                      99.9                                      0.1    99.6    0.4
      Fluconazole                                    ≤0.12         0.25                                      99.5                                      0.4    98.1    1.9
      Itraconazole                                   ≤0.06         0.12                                                                                               
      Posaconazole                                   0.03          0.06                                                                                       96.5    3.5
      Voriconazole                                   ≤0.008        0.015                                     99.9                                      0.0    99.0    1.0
      Amphotericin B                                 0.5           1                                                                                          100.0   0.0
  Candida glabrata (*n* = 374)                                                                                                                                        
      Rezafungin                                     0.06          0.12                                                                                       95.7    4.3
      Anidulafungin                                  0.06          0.12                                      94.4                                      3.2    96.8    3.2
      Caspofungin                                    0.03          0.06                                      97.1                                      2.1            
      Micafungin                                     0.015         0.03                                      96.0                                      2.4    93.3    6.7
      Fluconazole                                    2             32                                        91.4[^*c*^](#T3F3){ref-type="table-fn"}   8.6    85.6    14.4
      Itraconazole                                   0.5           2                                                                                          98.7    1.3
      Posaconazole                                   0.25          1                                                                                          93.0    7.0
      Voriconazole                                   0.06          1                                                                                          87.2    12.8
      Amphotericin B                                 1             1                                                                                          100.0   0.0
  Candida parapsilosis (*n* = 329)                                                                                                                                    
      Rezafungin                                     1             2                                                                                          100.0   0.0
      Anidulafungin                                  2             2                                         93.9                                      0.0    100.0   0.0
      Caspofungin                                    0.25          0.5                                       100.0                                     0.0            
      Micafungin                                     1             1                                         100.0                                     0.0    100.0   0.0
      Fluconazole                                    0.5           32                                        86.0                                      12.5   83.6    16.4
      Itraconazole                                   0.12          0.25                                                                                               
      Posaconazole                                   0.06          0.12                                                                                       100.0   0.0
      Voriconazole                                   ≤0.008        0.25                                      88.4                                      0.9    84.5    15.5
      Amphotericin B                                 0.5           1                                                                                          100.0   0.0
  Candida tropicalis (*n* = 196)                                                                                                                                      
      Rezafungin                                     0.03          0.06                                                                                       100.0   0.0
      Anidulafungin                                  0.03          0.06                                      99.0                                      1.0    98.0    2.0
      Caspofungin                                    0.015         0.06                                      99.0                                      1.0            
      Micafungin                                     0.03          0.06                                      99.0                                      1.0    96.4    3.6
      Fluconazole                                    0.25          1                                         96.9                                      2.6    94.9    5.1
      Itraconazole                                   0.12          0.5                                                                                        100.0   0.0
      Posaconazole                                   0.06          0.12                                                                                       92.9    7.1
      Voriconazole                                   0.015         0.06                                      96.9                                      0.0    96.9    3.1
      Amphotericin B                                 0.5           1                                                                                          100.0   0.0
  Candida krusei (*n* = 77)                                                                                                                                           
      Rezafungin                                     0.03          0.06                                                                                       100.0   0.0
      Anidulafungin                                  0.06          0.12                                      100.0                                     0.0    100.0   0.0
      Caspofungin                                    0.12          0.25                                      98.7                                      0.0            
      Micafungin                                     0.06          0.12                                      100.0                                     0.0    100.0   0.0
      Fluconazole                                    32            64                                                                                                 
      Itraconazole                                   0.5           1                                                                                          100.0   0.0
      Posaconazole                                   0.5           0.5                                                                                        100.0   0.0
      Voriconazole                                   0.25          0.5                                       96.1                                      1.3    96.1    3.9
      Amphotericin B                                 1             2                                                                                          100.0   0.0
  Candida dubliniensis (*n* = 93)                                                                                                                                     
      Rezafungin                                     0.06          0.12                                                                                       100.0   0.0
      Anidulafungin                                  0.03          0.12                                                                                       100.0   0.0
      Caspofungin                                    0.03          0.03                                                                                               
      Micafungin                                     0.03          0.03                                                                                       100.0   0.0
      Fluconazole                                    ≤0.12         0.25                                                                                       96.8    3.2
      Itraconazole                                   ≤0.06         0.25                                                                                               
      Posaconazole                                   0.03          0.06                                                                                               
      Voriconazole                                   ≤0.008        0.015                                                                                              
      Amphotericin B                                 0.5           0.5                                                                                                
  Cryptococcus neoformans var. *grubii* (*n* = 73)                                                                                                                    
      Rezafungin                                     \>4           \>4                                                                                                
      Anidulafungin                                  \>4           \>4                                                                                                
      Caspofungin                                    \>4           \>4                                                                                                
      Micafungin                                     \>4           \>4                                                                                                
      Fluconazole                                    2             4                                                                                          100.0   0.0
      Itraconazole                                   0.25          0.25                                                                                       93.5    6.5
      Posaconazole                                   0.12          0.25                                                                                       97.3    2.7
      Voriconazole                                   0.03          0.12                                                                                       100.0   0.0
      Amphotericin B                                 0.5           1                                                                                          52.1    47.9
  Aspergillus fumigatus (*n* = 183)                                                                                                                                   
      Rezafungin                                     0.015         0.03                                                                                       100.0   0.0
      Anidulafungin                                  0.015         0.03                                                                                               
      Caspofungin                                    0.015         0.03                                                                                       100.0   0.0
      Micafungin                                     ≤0.008        0.015                                                                                              
      Itraconazole                                   0.5           1                                                                                          98.4    1.6
      Posaconazole                                   0.25          0.5                                                                                                
      Voriconazole                                   0.25          0.5                                                                                        98.9    1.1
      Amphotericin B                                 1             2                                                                                          100.0   0.0
  *Aspergillus* section *Flavi* (*n* = 45)                                                                                                                            
      Rezafungin                                     ≤0.008        0.015                                                                                              
      Anidulafungin                                  ≤0.008        0.015                                                                                              
      Caspofungin                                    0.015         0.03                                                                                       100.0   0.0
      Micafungin                                     0.015         0.03                                                                                               
      Itraconazole                                   0.5           1                                                                                          100.0   0.0
      Posaconazole                                   0.25          0.5                                                                                        100.0   0.0
      Voriconazole                                   0.5           1                                                                                          100.0   0.0
      Amphotericin B                                 2             2                                                                                          100.0   0.0

![](AAC.00099-20-t0003)

Abbreviations: S, susceptible; R, resistant; WT, wild type; NWT, non-wild type.

Criteria were published in the CLSI M60 document ([@B40]). Epidemiological cutoff value (ECV) criteria were published in the CLSI M59 document ([@B41]). The ECVs for rezafungin and each species were determined from data in the present study.

Nonresistant is interpreted as susceptible-dose dependent.

###### 

Summary of *fks* alterations detected in *Candida* strains as part of the 2016 to 2018 rezafungin surveillance program[^*a*^](#T4F1){ref-type="table-fn"}

  Isolate   Country   Yr     Organism        MIC (μg/ml) by CLSI method   1,3-β-[d]{.smallcaps}-Glucan synthase mutation in:                                                     
  --------- --------- ------ --------------- ---------------------------- ---------------------------------------------------- ------ ------ ------- ---- ---------------------- ----
  1051621   Hungary   2018   C. tropicalis   0.25                         0.25                                                 0.12   0.12   WT      WT   NT                     NT
  1051641   Hungary   2018   C. glabrata     1                            1                                                    1      0.5    WT      WT   F659_del               WT
  1053234   Canada    2018   C. glabrata     0.12                         0.12                                                 0.06   0.06   WT      WT   WT                     WT
  1075570   Belgium   2018   C. glabrata     0.06                         0.12                                                 0.06   0.06   WT      WT   WT                     WT
  1078854   USA       2018   C. glabrata     0.06                         0.06                                                 0.06   0.06   WT      WT   F659_del               WT
  1078861   USA       2018   C. glabrata     2                            2                                                    1      1      WT      WT   S663P                  WT
  1085740   Spain     2018   C. tropicalis   0.06                         0.06                                                 0.06   0.12   WT      WT   NT                     NT
  1087598   USA       2018   C. glabrata     2                            4                                                    4      4      WT      WT   S663P                  WT
  997524    Mexico    2017   C. glabrata     0.5                          0.5                                                  0.25   0.06   F625S   WT   WT                     WT
  999721    Italy     2017   C. glabrata     0.06                         0.06                                                 0.06   0.06   WT      WT   WT                     WT
  1015009   Spain     2017   C. glabrata     0.5                          1                                                    0.5    0.25   WT      WT   Y657 deletion, F658Y   WT
  1020535   USA       2017   C. glabrata     0.25                         0.25                                                 0.12   0.06   WT      WT   WT                     WT
  1021070   France    2017   C. glabrata     1                            2                                                    0.5    0.5    WT      WT   S663P                  WT
  1025460   USA       2017   C. glabrata     0.5                          1                                                    0.5    1      S629P   WT   R665G                  WT
  1026179   Spain     2017   C. glabrata     1                            1                                                    0.25   0.25   WT      WT   Y657 deletion, F658Y   WT
  1034513   Ireland   2017   C. glabrata     2                            4                                                    2      0.5    WT      WT   S663P                  WT
  1034514   Ireland   2017   C. glabrata     0.25                         0.5                                                  0.12   0.12   WT      WT   S663P                  WT
  1034803   USA       2017   C. glabrata     0.12                         0.12                                                 0.06   0.06   WT      WT   WT                     WT
  1034763   Turkey    2017   C. tropicalis   0.06                         0.06                                                 0.25   0.12   WT      WT   NT                     NT
  1034766   Turkey    2017   C. tropicalis   0.12                         0.25                                                 0.03   0.06   WT      WT   NT                     NT
  1041544   Greece    2017   C. tropicalis   0.06                         0.06                                                 0.03   0.12   WT      WT   NT                     NT
  984357    Ireland   2016   C. albicans     0.25                         0.12                                                 1      1      S645P   WT   NT                     NT
  978825    Turkey    2016   C. albicans     0.12                         0.12                                                 0.12   0.06   WT      WT   NT                     NT
  948247    USA       2016   C. glabrata     0.06                         0.12                                                 0.03   0.03   WT      WT   WT                     WT
  949151    USA       2016   C. glabrata     0.03                         0.06                                                 0.06   0.12   WT      WT   WT                     WT
  970382    USA       2016   C. glabrata     0.25                         0.25                                                 0.12   0.12   S629P   WT   WT                     WT
  970397    USA       2016   C. glabrata     0.12                         0.25                                                 0.25   0.12   WT      WT   P667H                  WT
  974239    USA       2016   C. glabrata     0.25                         0.25                                                 0.06   0.12   S629P   WT   WT                     WT
  974249    USA       2016   C. glabrata     2                            2                                                    1      1      WT      WT   S663P                  WT
  978819    Turkey    2016   C. glabrata     0.25                         0.25                                                 0.06   0.06   WT      WT   WT                     WT
  983007    USA       2016   C. glabrata     0.12                         0.5                                                  0.06   0.12   WT      WT   F658_del               WT
  985673    USA       2016   C. glabrata     0.06                         0.12                                                 0.06   0.06   WT      WT   S663P                  WT
  936285    Germany   2016   C. krusei       0.12                         0.12                                                 0.25   0.12   WT      WT   NT                     NT
  954660    Italy     2016   C. krusei       0.015                        0.03                                                 0.06   0.06   WT      WT   NT                     NT
  975699    USA       2016   C. krusei       0.015                        0.06                                                 0.12   0.06   WT      WT   NT                     NT
  977046    Brazil    2016   C. krusei       0.015                        0.015                                                0.06   0.06   WT      WT   NT                     NT
  970388    USA       2016   C. tropicalis   2                            1                                                    \>8    2      S654P   WT   NT                     NT
  977041    Brazil    2016   C. tropicalis   1                            1                                                    2      1      F650S   WT   NT                     NT
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RFG, rezafungin; AFG, anidulafungin; CAS, caspofungin; MFG, micafungin; WT, wild type; NT, not tested.

###### 

Fluconazole resistance by geographic region for *Candida* species, SENTRY Program, 2016 to 2018[^*a*^](#T5F1){ref-type="table-fn"}

  Species                                              Region   No. of isolates tested   \% (no.) of isolates resistant
  ---------------------------------------------------- -------- ------------------------ --------------------------------
  C. albicans                                          APAC     118                      0.0 (0)
                                                       EUR      408                      0.0 (0)
                                                       LATAM    104                      1.0 (1)
                                                       NA       205                      1.0 (2)
                                                       Total    835                      0.4 (3)
  C. glabrata                                          APAC     36                       2.8 (1)
                                                       EUR      150                      6.0 (9)
                                                       LATAM    21                       0.0 (0)
                                                       NA       167                      13.2 (22)
                                                       Total    374                      8.6 (32)
  C. parapsilosis                                      APAC     29                       3.4 (1)
                                                       EUR      145                      24.8 (36)
                                                       LATAM    49                       0.0 (0)
                                                       NA       106                      3.8 (4)
                                                       Total    329                      12.5 (41)
  C. tropicalis                                        APAC     40                       5.0 (2)
                                                       EUR      62                       1.6 (1)
                                                       LATAM    49                       4.1 (2)
                                                       NA       45                       0.0 (0)
                                                       Total    196                      2.6 (5)
  C. dubliniensis[^*b*^](#T5F2){ref-type="table-fn"}   APAC     5                        0.0 (0)
                                                       EUR      30                       0.0 (0)
                                                       LATAM    4                        0.0 (0)
                                                       NA       54                       5.6 (3)
                                                       Total    93                       3.2 (3)

![](AAC.00099-20-t0005)

APAC, Asia-Pacific; EUR, Europe; LATAM, Latin America; NA, North America.

Percentage of wild-type isolates based on epidemiological cutoff value (ECV) criteria published in the CLSI M59 document ([@B41]).

Among the 374 C. glabrata isolates tested, 95.7% were inhibited by rezafungin (MIC~50/90~, 0.06/0.12 μg/ml) at the ECV cutoff value of ≤0.12 μg/ml ([Tables 2](#T2){ref-type="table"} and [3](#T3){ref-type="table"}). Micafungin (MIC~50/90~, 0.015/0.03 μg/ml), caspofungin (MIC~50/90~, 0.03/0.06 μg/ml), and anidulafungin (MIC~50/90~, 0.06/0.12 μg/ml), respectively, inhibited 96.0%, 97.1%, and 94.4% of these isolates at the current CLSI breakpoints ([@B40]). Mutations within the *fks* HS leading to amino acid alterations were found in 17 (68.0%) out of 25 C. glabrata isolates displaying echinocandin MIC values greater than the ECV ([Table 4](#T4){ref-type="table"}). The most common substitutions were *fks2* HS1 S663P (7 isolates), *fks2* HS1 with a deletion of F659 (F659_del) (2 isolates), *fks2* HS1 Y657_del/F658Y (2 isolates), and *fks1* HS1 S629P (2 isolates). The corresponding rezafungin MIC values ranged from 0.06 to 2 μg/ml (82.4% \> ECV \[0.12 μg/ml\]) for all 17 isolates with an *fks* mutation ([Table 4](#T4){ref-type="table"}). Among all C. glabrata isolates collected from 2016 to 2018, 8.6% displayed a fluconazole-resistant phenotype. Based on the ECV cutoff published by CLSI, 7.0% and 12.8% of these isolates were categorized as NWT to posaconazole and voriconazole, respectively ([@B40], [@B41]) ([Table 3](#T3){ref-type="table"}). High rates of resistance to fluconazole were seen in isolates from EUR (6.0%) and NA (13.2%) ([Table 5](#T5){ref-type="table"}). Not only was C. glabrata a rare cause of IC in LATAM ([Table 1](#T1){ref-type="table"}), but also it was less resistant to fluconazole (0.0%) than isolates from the other monitored regions ([Table 5](#T5){ref-type="table"}).

Rezafungin inhibited all C. parapsilosis isolates (*n* = 329) at the ECV of ≤4 μg/ml ([Table 2](#T2){ref-type="table"}). The activity of rezafungin (MIC~90~, 2 μg/ml) was similar to that observed for micafungin (MIC~90~, 1 μg/ml; 100.0% S) and anidulafungin (MIC~90~, 2 μg/ml; 93.9% S) and was 4-fold lower than that of caspofungin (MIC~90~, 0.5 μg/ml; 100.0% S) ([Tables 2](#T2){ref-type="table"} and [3](#T3){ref-type="table"}). Among the C. parapsilosis isolates, a total of 41 isolates (12.5%) were categorized as fluconazole resistant, and 36 of these strains (87.8%) were from European medical centers (24.8% fluconazole resistant) ([Table 5](#T5){ref-type="table"}). Although C. parapsilosis was common in LATAM (20.2% of *Candida* isolates, second in rank order) ([Table 1](#T1){ref-type="table"}), no fluconazole-resistant strains were detected among the 49 C. parapsilosis isolates tested ([Table 5](#T5){ref-type="table"}).

C. tropicalis isolates (*n* = 196) were largely susceptible to anidulafungin, caspofungin, and micafungin (99.0% S) ([Table 3](#T3){ref-type="table"}). Rezafungin (MIC~50/90~, 0.03/0.06 μg/ml) inhibited 97.4% of the isolates at the proposed ECV of ≤0.12 μg/ml ([Tables 2](#T2){ref-type="table"} and [3](#T3){ref-type="table"}). Among 7 C. tropicalis isolates categorized as NWT to echinocandin and submitted to *fks* sequencing, 2 harbored *fks1* HS1 mutations leading to amino acid alterations (S645P and F650S; [Table 4](#T4){ref-type="table"}). Both isolates were resistant to anidulafungin (MIC values, 1 μg/ml for both), caspofungin (MIC values, \>8 and 2 μg/ml), and micafungin (MIC values, 2 and 1 μg/ml) and NWT (MIC \> ECV; MIC values, 2 and 1 μg/ml) to rezafungin. The remaining 5 isolates did not contain *fks1* mutations, and 4 were WT to rezafungin (MIC values, ≤0.12 μg/ml). Fluconazole resistance was observed in 5 C. tropicalis isolates (2.6% of the total; [Table 5](#T5){ref-type="table"}). No fluconazole-resistant strains were found among the 45 C. tropicalis isolates from NA, and 5.0% of the isolates from APAC were resistant to fluconazole ([Table 5](#T5){ref-type="table"}).

Rezafungin (MIC~50/90~, 0.03/0.06 μg/ml) was active against 77 C. krusei isolates; 100.0% of the isolates were inhibited at ≤0.12 μg/ml, the ECV for this species (100.0% WT) ([Tables 2](#T2){ref-type="table"} and [3](#T3){ref-type="table"}). These isolates were susceptible to anidulafungin (MIC~50/90~, 0.06/0.12 μg/ml; 100.0% S), micafungin (MIC~50/90~, 0.06/0.12 μg/ml; 100.0% S), and caspofungin (MIC~50/90~, 0.12/0.25 μg/ml; 98.7% S) ([Table 3](#T3){ref-type="table"}) according to CLSI breakpoint criteria. Four C. krusei isolates were NWT to one or more echinocandins, but none of these isolates were shown to possess an *fks* mutation: all were WT to rezafungin ([Table 4](#T4){ref-type="table"}). Voriconazole was active against 96.1% of the C. krusei isolates, and all isolates displayed a posaconazole WT phenotype ([Table 3](#T3){ref-type="table"}).

All echinocandins (anidulafungin \[MIC~50/90~, 0.03/0.12 μg/ml; 100.0% WT\], caspofungin \[MIC~50/90~, 0.03/0.03 μg/ml\], and micafungin \[MIC~50/90~, 0.03/0.03 μg/ml; 100.0% WT\]) displayed activity similar to that of rezafungin (MIC~50/90~, 0.06/0.12 μg/ml; 100.0% WT) ([Tables 2](#T2){ref-type="table"} and [3](#T3){ref-type="table"}) against 93 C. dubliniensis isolates. Three isolates were resistant/NWT to fluconazole, and all three were from patients hospitalized in NA (5.6% resistant) ([Table 5](#T5){ref-type="table"}).

Fluconazole (MIC~50/90~, 2/4 μg/ml) and other azoles (MIC~50/90~ values, 0.12/0.25 and 0.03/0.12 μg/ml for posaconazole and voriconazole, respectively) displayed good activity against C. neoformans, whereas echinocandins, including rezafungin, displayed limited activity.

The activity of rezafungin against 183 A. fumigatus isolates tested (MEC~50/90~, 0.015/0.03 μg/ml; all were inhibited at the ECV of ≤0.03 μg/ml \[100.0% WT\]) was comparable to that of caspofungin (MEC~50/90~, 0.015/0.03 μg/ml), anidulafungin (MEC~50/90~, 0.015/0.03 μg/ml; 100% WT), and micafungin (MEC~50/90~, ≤0.008/0.015 μg/ml). Voriconazole and itraconazole showed WT MIC values against over 98% of the A. fumigatus isolates ([Table 3](#T3){ref-type="table"}).

Against Aspergillus flavus species complex isolates (*n* = 45), comparable activity was observed for rezafungin (MEC~50/90~, ≤0.008/0.015 μg/ml) and the other echinocandins, such as caspofungin (MEC~50/90~, 0.015/0.03 μg/ml; 100% WT), anidulafungin (MEC~50/90~, ≤0.008/0.015 μg/ml), and micafungin (0.015/0.03 μg/ml). A WT phenotype was observed for itraconazole, posaconazole, and voriconazole against all A. flavus species complex isolates ([Table 3](#T3){ref-type="table"}).

DISCUSSION {#s3}
==========

This study provides a robust estimate of the WT MIC/MEC distributions of rezafungin for 6 species of *Candida* as well as A. fumigatus and A. flavus and expands upon our earlier rezafungin activity observations ([@B31][@B32][@B33]). Although establishing definitive ECVs and clinical breakpoints (CBPs) for rezafungin requires multicenter studies involving larger numbers of isolates of each species than the numbers used in this study ([@B39]), we suggest that the ECV determined using CLSI BMD methods in the present study is ≤0.12 μg/ml for C. albicans, C. tropicalis, C. glabrata, and C. krusei (98.5% of 1,482 isolates; [Table 2](#T2){ref-type="table"}), ≤0.25 μg/ml for C. dubliniensis (100.0% of 93 isolates), ≤4 μg/ml for C. parapsilosis (100.0% of 329 isolates), and ≤0.03 μg/ml for A. fumigatus (100.0% of 183 isolates) ([Table 2](#T2){ref-type="table"}). Notably, these values are far below the peak plasma concentrations of 22 to 30 μg/ml achievable at the 400-mg dose ([@B15], [@B26], [@B27]) and are equivalent to the ECVs established for these species/species groups and the clinically available echinocandins ([@B41][@B42][@B43]).

Additional support for these ECVs is found in a recent multicenter study of rezafungin activity against *Candida* spp. determined using the EUCAST BMD method and both visual and statistical means of determining possible wild-type upper-limit (WT-UL) values ([@B28]). In the four-laboratory study, WT-UL cutoffs were proposed for C. glabrata (0.125 μg/ml), C. krusei (0.125 μg/ml), and C. parapsilosis (4 μg/ml). Although interlaboratory variation precluded proposing cutoffs for C. albicans and C. tropicalis, the WT-UL statistical 97.5% endpoint was 0.063 μg/ml for C. albicans and 0.25 μg/ml for C. tropicalis ([@B28]). These values compare favorably with the ECVs generated by the CLSI BMD method in the present study. Although an essential agreement rate (±2 dilution steps) of 92.0% for C. albicans and 100.0% for C. glabrata, C. parapsilosis, C. tropicalis, and C. krusei between CLSI and EUCAST methods for rezafungin was observed previously ([@B31]), alignment between CLSI and EUCAST susceptibility profiles and breakpoints is yet to be determined, as significant interlaboratory EUCAST MIC variability (likely attributed to nonspecific binding of the drug to plastics) has been identified for rezafungin against a more susceptible collection of *Candida* spp. ([@B28], [@B44]).

As seen in [Table 4](#T4){ref-type="table"}, the highest rezafungin MIC values for *fks* mutant strains of C. albicans and C. glabrata were 0.25 μg/ml and 2 μg/ml, respectively. Both of these MIC values for mutant strains are within the range of concentrations that Bader et al. ([@B20]) estimated would achieve percent probabilities of PK-PD target attainment of 100% through week 6, suggesting that weekly regimens of rezafungin can achieve exposures associated with efficacy against some *fks* mutant *Candida* isolates ([@B20]). In addition, the same study showed that the mutant prevention concentration, the concentration of drug that would inhibit emerging resistant mutants, for both rezafungin and micafungin was 16 μg/ml ([@B27]). Given that the high plasma drug exposure of rezafungin easily exceeds the mutant prevention concentration for *Candida*, a possible advantage of rezafungin may be to prevent the development of resistance to the echinocandin class of antifungal agents ([@B20], [@B22], [@B24], [@B27]).

Expert panel guidelines from both NA ([@B5]) and EUR ([@B12]) favor step-down therapy to fluconazole or voriconazole for patients with candidiasis in specific clinical situations, that is, when clinical improvement and the clearance of *Candida* from the bloodstream are achieved by the initial echinocandin therapy. In addition, the organism must be susceptible to fluconazole (e.g., C. albicans, C. parapsilosis, and C. tropicalis) or voriconazole (e.g., C. krusei). Unfortunately, antifungal susceptibility testing is still not routinely available in many patient care settings. In these circumstances, clinicians are forced to rely on simple identification of the *Candida* species as a predictor of fluconazole susceptibility ([@B5], [@B12]). In most instances, isolates of C. albicans, C. parapsilosis, and C. tropicalis are considered to be reliably susceptible to fluconazole ([@B16]), whereas C. glabrata and C. krusei are considered to be intrinsically less susceptible or resistant and are suboptimal targets for using fluconazole ([@B5], [@B12]). This approach may be seriously flawed if fluconazole resistance emerges among the traditionally susceptible species. Concern regarding this approach has been raised by Oxman et al. ([@B45]), who found that despite the small proportion of C. albicans, C. parapsilosis, and C. tropicalis isolates with resistance/decreased susceptibility to fluconazole, these species comprised 36% of the reduced-susceptibility group (including C. glabrata and C. krusei), potentially compromising therapy with the resultant clinical failure. These concerns are supported by data from the current survey showing that the rate of resistance to fluconazole was 0.4% for C. albicans, 12.5% for C. parapsilosis, and 2.6% for C. tropicalis ([Tables 3](#T3){ref-type="table"} and [5](#T5){ref-type="table"}). In aggregate, these three normally susceptible species account for 31% of all fluconazole-resistant isolates. Species identification should be used cautiously as the sole criterion for anti-*Candida* agent selection ([@B5], [@B45]).

The increased rate of fluconazole resistance among the C. parapsilosis (12.5% overall) and C. tropicalis (2.6% overall) isolates in the present study is important, as these species are the non-C. albicans species most commonly isolated in LATAM ([Table 1](#T1){ref-type="table"}). Although less common than C. glabrata in EUR, the rate of fluconazole resistance of 24.8% among C. parapsilosis isolates exceeds the rate observed among C. glabrata (6.0%) isolates and is cause for alarm ([Table 5](#T5){ref-type="table"}).

This survey has some limitations, as noted elsewhere ([@B16]): the SENTRY Surveillance Program is a sentinel surveillance and is not population based; therefore, we may over- or underestimate the activity of the tested agents. In addition, we do not collect data concerning antifungal use or outcomes of therapy. The purpose of the SENTRY Program is to identify trends in antifungal resistance and to document the emergence of new species as well as the activity of new and established agents against key fungal pathogens. The broad geographic distribution, the longitudinal nature of the surveillance, and the use of molecular and proteomic identification methods and determination of resistance mechanisms are strengths of the SENTRY Program.

In conclusion, we have provided additional *in vitro* data demonstrating the activity of rezafungin against a collection of largely echinocandin-WT isolates of *Candida* spp., C. neoformans, A. fumigatus, and the A. flavus species complex. Given these findings, we suggest that MIC values of ≤0.12 μg/ml (C. albicans, C. glabrata, C. tropicalis, and C. krusei), ≤0.25 μg/ml (C. dubliniensis), and ≤4 μg/ml (C. parapsilosis) and a MEC of ≤0.03 μg/ml (A. fumigatus) approximate the ECV/WT-UL MIC/MEC distributions for rezafungin and the common species of *Candida* and *Aspergillus*. Further evaluations including at least 100 MIC values per species tested by three different laboratories should be performed to define the ECVs for rezafungin, a fundamental step in establishing clinical breakpoints.

This survey provides new information regarding emerging fluconazole resistance among C. parapsilosis and C. tropicalis clinical isolates from geographic regions beyond NA, in addition to demonstrating evidence of the sustained activity of rezafungin and the other echinocandins against *Candida* and *Aspergillus* species. Whereas the highest rates of fluconazole resistance in NA isolates were seen in C. glabrata (13.2%), fluconazole-resistant C. parapsilosis (24.8%) was most prominent in EUR and fluconazole-resistant C. tropicalis was most prominent in APAC (5.0%) and LATAM (4.1%). In all three instances, the rate of fluconazole resistance was highest in species of *Candida* other than C. glabrata. Species identification should be used cautiously as the sole criterion for selecting antifungal therapy.

MATERIALS AND METHODS {#s4}
=====================

Organisms. {#s4.1}
----------

During 2016 to 2018, 2,205 nonduplicate fungal isolates were prospectively collected from 57 medical centers located in North America (723 isolates; 18 sites \[17 sites in the United States and 1 site in Canada\]), EUR (927 isolates; 22 sites, 14 countries), the APAC region (279 isolates; 11 sites, 5 countries), and LATAM (276 isolates; 6 sites, 4 countries). Isolates were recovered from the following sources: bloodstream infections (*n* = 1,460 isolates), pneumonia in hospitalized patients (*n* = 306), intra-abdominal infections (*n* = 32), skin and skin structure infections (*n* = 106), urinary tract infections (*n* = 35), and other or nonspecified body sites (*n* = 266).

Fungal identification methods. {#s4.2}
------------------------------

Yeast isolates were subcultured and screened using CHROMagar *Candida* (Becton, Dickinson, Sparks, MD) to ensure purity. Matrix-assisted laser desorption ionization--time of flight mass spectrometry (MALDI-TOF MS) was applied for the identification of all yeast isolates using a MALDI Biotyper apparatus according to the manufacturer's instructions (Bruker Daltonics, Billerica, MA). Isolates that were not identified by proteomic methods were submitted to the previously described sequencing-based methods ([@B43], [@B46], [@B47]).

Molds were cultured and identified by MALDI-TOF MS or DNA sequencing analysis when an acceptable identification was not achieved by MALDI-TOF MS. The sequences of the 28S ribosomal DNA and β-tubulin genes of *Aspergillus* spp. were analyzed ([@B47][@B48][@B50]).

Nucleotide sequences were analyzed using Lasergene software (DNAStar, Madison, WI, USA) and compared to available sequences using the BLAST program (<https://blast.ncbi.nlm.nih.gov/Blast.cgi>).

Antifungal susceptibility testing. {#s4.3}
----------------------------------

All isolates were tested by CLSI BMD methods as described in documents M27 ([@B37]) and M38 ([@B38]). Only systemically active antifungal agents were tested, including rezafungin, anidulafungin, micafungin, caspofungin, itraconazole, fluconazole, voriconazole, posaconazole, and amphotericin B. The ranges of antifungal agent concentrations tested were 0.008 to 4 μg/ml for itraconazole, posaconazole, and voriconazole, 0.12 to 2 μg/ml for amphotericin B, and 0.12 to 128 μg/ml for fluconazole. The echinocandin concentration range tested during 2016 and 2017 was 0.008 to 4 μg/ml, whereas this range was expanded to 0.002 to 4 μg/ml in 2018. MIC results were determined visually after 24 h (*Candida* spp.), 48 h (*Aspergillus* spp.), or 72 h (C. neoformans) of incubation at 35°C. Azole and echinocandin MIC values against yeasts were read as the lowest concentration of drug that resulted in ≥50% inhibition of growth relative to that of the growth control. Complete (100%) inhibition was used to determine itraconazole, posaconazole, and voriconazole MIC values against *Aspergillus* spp. and amphotericin B MIC values against yeasts and molds. Echinocandin minimum effective concentration (MEC) values, including those of rezafungin, were read against *Aspergillus* spp. as described in CLSI document M38 ([@B38]).

Echinocandin, fluconazole, and voriconazole susceptibility categories were applied for the five most common species of *Candida* (C. albicans, C. tropicalis, C. parapsilosis, C. glabrata, and C. krusei) following CLSI clinical breakpoints (CBPs) ([@B40]). Epidemiological cutoff values (ECVs/ECOFFs) were used to differentiate wild-type (WT) from non-wild-type (NWT) isolates of the species for which there are no CLSI CBPs ([@B39], [@B41]). Neither CBPs nor ECVs/ECOFFs have been determined by CLSI methods for rezafungin against *Candida*, *Aspergillus*, or *Cryptococcus* spp. For comparison, we established tentative ECVs for rezafungin and each species using the iterative statistical method recommended by CLSI ([@B28], [@B32], [@B39][@B40][@B41]). These ECVs must be considered tentative, given the CLSI requirement that ECVs be determined using MIC/MEC data acquired from a minimum of three different laboratories including at least 100 MIC/MEC values from 100 individual isolates, all determined by CLSI reference methods ([@B39]).

QC. {#s4.4}
---

To ensure proper test conditions and procedures, concurrent quality control (QC) testing was performed. The QC strains recommended by CLSI included C. krusei ATCC 6258, C. parapsilosis ATCC 22019, A. flavus ATCC 204304, and A. fumigatus ATCC MYA-3626.

Screening for 1,3-β-[d]{.smallcaps}-glucan synthase mutations. {#s4.5}
--------------------------------------------------------------

All *Candida* isolates that were echinocandin resistant or that showed MIC values higher than the ECV for any echinocandin were submitted to whole-genome sequencing for detecting mutations in the HS regions of *fks1* and *fks2* (C. glabrata only) as described previously ([@B43], [@B48], [@B50]).
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